ArticleJournal of thoracic disease2026
Differences in pulmonary cavity features among drug-sensitive pulmonary tuberculosis and multidrug/extensively-resistant pulmonary tuberculosis: a multi-national multi-center computed tomography-based study.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary cavities (PC) are known to be more prevalent among multidrug-resistant pulmonary tuberculosis (MDR)/extensively drug-resistant tuberculosis (XDR) patients than among drug-sensitive tuberculosis (DS) patients. This study aims to clarify how the interaction between Methods: Eastern European patient data were from the NIAID TB (National Institute of Allergy & Infectious Diseases Tuberculosis) Portals Program registered before January 2019. Chinese patients were from Shenzhen, China, treated between April 2017 and February 2019. There were in total 244 DS cases (222 new patients and 22 previously treated patients), 344 MDR cases (188 new patients and 156 previously treated patients), and 155 XDR cases (36 new patients and 119 previously treated patients). The first chest computed tomography (CT) images were analysed. PC were counted only for those with a lumen diameter >5 mm. Multiple cavities in a single consolidation were counted as one cavity. Calcified lesions in the lungs, as a sign of chronicity, were also recorded. Results: In new patients, there was no difference in lung lesion calcification prevalence among DS (13.5%), MDR (14.4%), and XDR (13.9%). In previously treated patients, lung calcification prevalence was 36.4% for DS, 44.9% for MDR, and 45.4% for XDR. For new patients, the PC prevalence was higher for MDR cases than for DS cases (41% Conclusions: MDR/XDR patients exhibit significantly higher PC prevalence and more extensive pulmonary involvement compared to DS patients, which are not totally determined by the length of disease history. Compared with literature reports, the prevalence of PC and the PC number per positive case were comparatively low in this study. Taking all results together, PC number ≥3 offers reasonable specificity for suggesting the diagnosis of MDR, though the sensitivity would be low.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.